Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 32

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 32
---
 for the following 2024 named executive officers:

| Name                |     | Position                                  |
| Chad Robins         |     | Chief Executive Officer and Chairman      |
| Tycho Peterson      |     | Former Chief Financial Officer            |
| Kyle Piskel         |     | Chief Financial Officer                   |
| Sharon Benzeno, PhD |     | Chief Commercial Officer, Immune Medicine |
| Harlan Robins, PhD  |     | Chief Scientific Officer                  |
| Julie Rubinstein    |     | President and Chief Operating Officer     |

2024 Say-on-PayVoting Results, Our Responsiveness, and Pay-Versus-PerformanceAlignment We became a public company in 2019 and continue our journey of growth and maturation today. As a result, we annually assess the competitiveness of our executive compensation and governance policies and practices relative to other similarly-situated companies. Our executive compensation program is structured to incentivize and reward strong corporate performance that leads to long-term value creation. The corporate performance portion of our annual non-equityincentive awards draws directly from the achievement of corporate goals we establish each year. We continued to engage in one-on-oneshareholder engagement discussions with investors in 2024 to obtain additional feedback about our corporate governance processes, compensation philosophy and executive compensation program design. A number of these discussions included the participation by Dr. Hershberg, chair of our compensation and human capital committee, and at least one of these discussions included participation by Dr. Pellini, a member of our nominating and corporate governance committee. We consider the feedback heard in these outreach conversations and our overall Say-on-Paysupport level (87.1% in our most recent vote) when designing our executive compensation program. We took the following actions in 2024 to specifically address points of feedback received in meetings with several of our shareholders and director Dr. Hershberg concerning our compensation program:

| • |     | Diligently Managed Burn Rate: In light of our stock price in early 2024, we pursued a flat-share grant approach for the executive team in aggregate. This action was taken to manage overall equity dilution and resulted in meaningfully reduced annual equity awards on a grant date fair value basis for our executives than in previous years. |

| • |     | Continued to Expand PSU Program: We replaced time-based stock option grants with performance stock units (“PSUs”) for our Chief Financial Officer (including our internally promoted Chief Financial Officer) and President and Chief Operating Officer in 2024. Our